46ad74b00d
- Source: inbox/queue/2026-02-18-medrxiv-oregon-psilocybin-services-mental-health-outcomes.md - Domain: health - Claims: 0, Entities: 2 - Enrichments: 3 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
49 lines
No EOL
2.1 KiB
Markdown
49 lines
No EOL
2.1 KiB
Markdown
# Oregon Measure 109
|
|
|
|
**Type:** State psilocybin regulation
|
|
**Jurisdiction:** Oregon, USA
|
|
**Status:** Active (approved 2020, implemented 2023)
|
|
**Domain:** Psychedelic policy
|
|
|
|
## Overview
|
|
|
|
Measure 109 is Oregon's voter-approved ballot initiative establishing a state-regulated psilocybin services program. Passed in November 2020, it created the first legal framework in the United States for supervised psilocybin administration for therapeutic purposes outside of clinical trials.
|
|
|
|
## Regulatory Framework
|
|
|
|
- State licensing of psilocybin service centers
|
|
- Facilitator training and certification requirements
|
|
- Minimum protocol requirements for preparation, administration, and integration
|
|
- No medical diagnosis required for access
|
|
- Services available to adults 21+
|
|
|
|
## Implementation
|
|
|
|
The program became operational in 2023, with licensed service centers beginning to offer psilocybin sessions. Individual centers may exceed minimum regulatory requirements with enhanced screening, preparation, and integration protocols.
|
|
|
|
## Access and Equity Issues
|
|
|
|
First published outcomes data (Bendable Therapy, 2026) revealed significant demographic disparities:
|
|
- 87.5% of clients are white
|
|
- 84.1% have completed higher education
|
|
- 77.3% earn above $50K annually
|
|
- 46.6% travel from out of state
|
|
- Program functions partly as "psilocybin tourism" destination
|
|
|
|
These patterns indicate the program is not reaching underserved populations despite being designed for therapeutic mental health access.
|
|
|
|
## Clinical Outcomes
|
|
|
|
First naturalistic study (n=88, 30-day follow-up) showed large effect sizes:
|
|
- Depression: -4.63 points PHQ-8, d=0.90
|
|
- Anxiety: -4.85 points GAD-7, d=1.04
|
|
- Wellbeing: +10.67 points WHO-5, d=2.14
|
|
- Clinically significant HPPD at 30 days: 0%
|
|
- Lingering negative effects: 3.4%
|
|
|
|
## Timeline
|
|
|
|
- **2020-11** — Measure 109 approved by Oregon voters
|
|
- **2023** — Program implementation begins, licensed service centers open
|
|
- **2024-03** — First prospective outcomes study begins (Bendable Therapy)
|
|
- **2026-02-18** — First published outcomes study released as medRxiv preprint, revealing both strong clinical effects and significant demographic access disparities |